Drug intelligence / Profile preview

HYX1-derived exosomes

Development stage: Preclinical
Lead developer: Beijing YouAn Hospital
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

HYX1-derived exosomes (HYX1-Exos) are extracellular vesicles derived from the human liver stem cell line HYX1. They are being developed for the treatment of acute liver failure (ALF). The therapeutic mechanism of HYX1-derived exosomes involves the delivery of protective microRNA cargoes, specifically miR-4492 and miR-4508. These microRNAs target and inhibit IQGAP1 (IQ motif containing GTPase activating protein 1) and SLC7A11 (solute carrier family 7 member 11), thereby suppressing disulfidptosis (a form of programmed cell death) and mitigating hepatocyte damage.

Other names: HYX1-derived exosomal miR-4492HYX-1-derived exosomal miR-4492HYX 1-derived exosomal miR-4492human liver stem cell line HYX1-derived exosomes

Beyond the preview

Go deeper on HYX1-derived exosomes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HYX1-derived exosomes.